Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis

Cancer Research

Volumn 67, Issue 5, 2007, Pages 1902-1909

  D'Armiento, Jeanine ^a   Imai, Kazushi ^a   Schiltz, John ^b   Kolesnekova, Natalya ^a   Sternberg, David ^a   Benson, Kathleen ^b   Pardo, Annie ^c   Selman, Moises ^c   Smolarek, Theresa ^d   Vundavalli, Murty ^a   Sonnet, Joshua ^a   Szabolcs, Matthias ^a   Chada, Kiran ^b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EMBRYO; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG TUMOR; LYMPHANGIOMYOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SMOOTH MUSCLE FIBER;

ANIMALS; FEMALE; HMGA2 PROTEIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; MYOCYTES, SMOOTH MUSCLE;

EID: 33947238378     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1122     Document Type: Article

References (49)

1. Grosschedl R, Giese K, Pagel J. HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet 1994;10:94-100.
2. Zhou X, Chada K. HMGI family proteins: architectural transcription factors in mammalian development and cancer. Keio J Med 1998;47:73-7.
3. Manfioletti G, Giancotti V, Bandiera A, et al. cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Res 1991;19:6793-7.
4. Wolffe AP. Architectural transcription factors. Science 1994;264:1100-1.
5. Carey M. The enhanceosome and transcriptional synergy. Cell 1998;92:5-8.
6. Thanos D, Du W, Maniatis T. The high mobility group protein HMG I(Y) is an essential structural component of a virus-inducible enhancer complex. Cold Spring Harb Symp Quant Biol 1993;58:73-81.
7. Xiang X, Benson KF, Chada K. Mini-mouse: disruption of the pygmy locus in a transgenic insertional mutant. Science 1990;247:967-9.
8. Zhou X Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995; 376:771-4.
9. Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 1998; 23:350-7.
10. Rogalla P, Drechsler K, Frey G, et al. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 1996;149:775-9.
11. Ashar HR, Fejzo MS, Tkachenko A, et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 1995;82:57-65.
12. Bol S, Wanschura S, Thode B, et al. An endometrial polyp with a rearrangement of HMGI-C underlying a complex cytogenetic rearrangement involving chromosomes 2 and 12. Cancer Genet Cytogenet 1996;90:88-90.
13. Kazmierczak B, Rosigkeit J, Wanschura S, et al. HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas: a survey of 30 tumors. Oncogene 1996;12:515-21.
14. Schoenberg Fejzo M, Ashar HR, Krauter KS, et al. Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that in lipomas. Genes Chromosomes Cancer 1996;17:1-6.
15. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 1995;10: 436-44.
16. Tkachenko A, Ashar HR, Meloni AM, Sandberg AA, Chada KK. Misexpression of disrupted HMGI architectural factors activates alternative pathways of tumorigenesis. Cancer Res 1997;57:2276-80.
17. Rubin E, Farber JL. Respiratory system. In: Pathology. Philadelphia: Lippincott Co.; 1988.
18. Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999;115:1041-52.
19. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J 2006;27:1056-65.
20. Kalassian KG, Doyle R, Kao P, Ruoss S, Raffin TA. Lymphangioleiomyomatosis: new insights. Am J Respir Crit Care Med 1997;155:1183-6.
21. Duncan M, DiCicco-Bloom EM, Xiang X, Benezra R, Chada K. The gene for the helix-loop-helix protein, Id, is specifically expressed in neural precursors. Dev Biol 1992;154:1-10.
22. Cattoretti G, Pileri S, Parravicini C, et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 1993;171:83-98.
23. Wang J, Niu W, Nikiforov Y, et al. Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice. J Clin Invest 1997;100:1425-39.
24. Theiler K. The house mouse; developmment and normal stages from fertilization to 4 weeks of age. Berlin: Springer-Verlag; 1972.
25. DeHaan RL, Ursprung H. Organogenesis. New York: Holt Rinehart and Winston; 1965.
26. Bonetti F, Chiodera PL, Pea M, et al. Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB45 for diagnosis. Am J Surg Pathol 1993;17:1092-102.
27. Kwon BS. Pigmentation genes: the tyrosinase gene family and the pmel 17 gene family. J Invest Dermatol 1993;100:134-40S.
28. McGraw DW, Forbes SL, Kramer LA, et al. Transgenic overexpression of β(2)-adrenergic receptors in airway smooth muscle alters myocyte function and ablates bronchial hyperreactivity. J Biol Chem 1999;274: 32241-7.
29. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157: 199-203.
30. Kaltreider HB. Hypersensitivity pneumonitis. West J Med 1993;159:570-8.
31. Lee KS, Chung MP. Idiopathic interstitial pneumonias: clinical findings, pathogenesis, pathology and radiologic findings. J Korean Med Sci 1999;14:113-27.
32. Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 1999;21:327-36.
33. Jones AC, Shyamsundar MM, Thomas MW, et al. Comprehensive mutation analysis of TSC1 and TSC2 and pheuotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999;64:1305-15.
34. Torres VE, King BF, Holley KE, Blute ML, Gomez MR. The kidney in the tuberous sclerosis complex. Adv Nephrol Necker Hosp 1994;23:43-70.
35. Capron F, Ameille J, Leclerc P, et al. Pulmonary lymphangioleiomyomatosis and Bourneville's tuberous sclerosis with pulmonary involvement: the same disease? Cancer 1983;52:851-5.
36. Castro M, Shepherd CW, Gomez MR, Lie JT, Ryu JH. Pulmonary tuberous sclerosis. Chest 1995;107: 189-95.
37. Valensi QJ. Pulmonary lymphangiomyoma, a probable forme frust of tuberous sclerosis. A case report and survey of the literature. Am Rev Respir Dis 1973;108:1411-5.
38. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 2000;97:6085-90.
39. Sato T, Seyama K, Fujii H, et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 2002; 47:20-8.
40. Henske EP, Wessner LL, Golden J, et al. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 1997;151:1639-47.
41. Johnson SR, Clelland CA, Ronan J, Tattersfield AE, Knox AJ. The TSC-2 product tuberin is expressed in lymphangioleiomyomatosis and angiomyolipoma. Histopathology 2002;40:458-63.
42. Niida Y, Stemmer-Rachamimov AO, Logrip M, et al. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 2001;69:493-503.
43. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179-93.
44. + channel (α-ENaC) transcription by Ras activation in salivary epithelial cells. J Biol Chem 2001;276:29805-14.
45. Burlew BP, Shames JM. Lymphangiomyomatosis: hormonal implications in etiology and therapy. South Med J 1991;84:1247-9.
46. Eliasson AH, Phillips YY, Tenholder MF. Treatment of lymphangioleiomyomatosis. A meta-analysis. Chest 1989;96:1352-5.
47. Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995;151: 527-33.
48. Radermecker M, Broux R, Corhay JL, Limet R, Radermecker M. Failure of buserelin-induced medical castration to control pulmonary lymphangiomyomatosis in two patients. Chest 1992;101:1724-6.
49. Urban T, Kuttenn F, Gompel A, Marsac J, Lacronique J. Pulmonary lymphangiomyomatosis. Follow-up and long-term outcome with antiestrogen therapy; a report of eight cases. Chest 1992;102:472-6.